Can you provide the last earnings date for CANDEL THERAPEUTICS INC?
CANDEL THERAPEUTICS INC (CADL) last reported earnings on 11/13/2025.
NASDAQ:CADL • US1374041093
Past quarterly earnings results for CANDEL THERAPEUTICS INC (CADL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.21 | -0.19 | -11.20% | - | - | - | ||
| Q2 2025 | -0.09 | -0.17 | 48.10% | - | - | - | ||
| Q1 2025 | 0.13 | -0.31 | 142.48% | - | - | - | ||
| Q4 2024 | -0.40 | -0.23 | -72.38% | -5.26% | - | - | ||
| Q3 2024 | - | - | - | - | ||||
| Q2 2024 | - | - | - | - | ||||
| Q1 2024 | - | - | - | - | ||||
| Q4 2023 | -0.38 | -0.16 | -132.84% | -111.11% | - | -100.00% | ||
| Q3 2023 | -0.31 | -0.19 | -59.96% | -3.33% | - | -100.00% | ||
| Q2 2023 | -0.34 | -0.30 | -11.67% | -6.25% | - | -100.00% | ||
| Q1 2023 | -0.33 | -0.36 | 7.56% | -3.13% | - | -100.00% | ||
| Q4 2022 | -0.18 | -0.32 | 43.44% | -158.06% | 31K | 23.123K | 34.06% | - |
| Q3 2022 | -0.30 | -0.36 | 16.68% | -15.38% | 31K | 30.6K | 1.31% | - |
| Q2 2022 | -0.32 | -0.42 | 23.01% | -3.23% | 31K | - | - | |
| Q1 2022 | -0.32 | -0.31 | -1.86% | - | 31K | 15.3K | 102.61% | - |
| Q4 2021 | 0.31 | -0.33 | 194.98% | - | 31K | 15.3K | 102.61% | - |
| Q3 2021 | -0.26 | -0.30 | 12.10% | - | 31K | 40.8K | -24.02% | - |
| Q2 2021 | -0.31 | -0.12 | -153.27% | - | 31K | 20.4K | 51.96% | - |
| Q1 2021 | - | - | 31K | - | - | |||
| Q4 2020 | - | - | 31K | - | - | |||
| Q3 2020 | - | - | 31K | - | - | |||
| Q2 2020 | - | - | 31K | - | - | |||
| Q1 2020 | - | - | 31K | - | - |
Notes
CANDEL THERAPEUTICS INC (CADL) last reported earnings on 11/13/2025.
CANDEL THERAPEUTICS INC (CADL) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, CANDEL THERAPEUTICS INC (CADL) has beaten EPS estimates in 2 out of 4 releases.